European Union & AstraZeneca
6 shared events · Importance 3 · Last updated Jun 12, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
European Union: The European Union's In Vitro Diagnostic Regulation (IVDR) provided the regulatory framework for the approval of the VENTANA MMR RxDx Panel, enabling its availability in member countries.
AstraZeneca: AstraZeneca benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Durvalumab and Olaparib therapies, potentially increasing the drugs' market reach.
Jun 11, 2026 · 6 articles
Regulatory
European Union: The EU is reviewing mFLUSIVA, which could expand Moderna's market access.
AstraZeneca: AstraZeneca's flu vaccine portfolio could be affected by the entry of mFLUSIVA.
Aug 05, 2026 · 105 articles
Accidents
European Union: A spokesperson for the European Union>>> stated that the risk of an Ebola outbreak in Europe is 'very low', indicating monitoring of the situation but no immediate alarm for the region.
AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.
May 18, 2026 · 505 articles
Business
European Union: Regulatory jurisdiction where EMA PRIME designation and Orphan Drug designation were granted.
AstraZeneca: Collaborator with Innate on monalizumab, mentioned as part of Innate's partnered assets, not directly affected by this deal.
Aug 10, 2026 · 10 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how European Union and AstraZeneca interact across events, view sentiment trends, and discover connected entities.
Open Dashboard